PCRX - Pacira BioSciences, Inc.
IEX Last Trade
19.43
4.780 24.601%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:00:00 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
19.80%
PREVIOUS CLOSE
CHG
CHG%
$14.65
4.78
32.63%
Fundamental analysis
33%
Profitability
28%
Dept financing
32%
Liquidity
75%
Performance
26%
Performance
5 Days
2.58%
1 Month
11.77%
3 Months
39.97%
6 Months
-31.40%
1 Year
-41.09%
2 Year
-50.92%
Key data
Stock price
$19.43
DAY RANGE
$14.65 - $19.18
52 WEEK RANGE
$12.75 - $35.95
52 WEEK CHANGE
-$43.25
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: David M. Stack
Region: US
Website: pacira.com
Employees: 720
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: pacira.com
Employees: 720
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectionable suspension. iovera system produces controlled doses of cold temperature only to targeted nerves.
Recent news